3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Bevacizumab
3
durvalumab
2
atezolizumab
2
Nivolumab
2
Ipilimumab
2
Hepatectomy
2
tremelimumab
1
trastuzumab deruxtecan
1
poly ICLC
1
pembrolizumab
1
brodalumab
1
Whole Genome Sequencing
1
Standard of Care
1
Specimen Handling
1
Radionuclide Imaging
1
Pluvicto
1
Platinum
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Immunoglobulin G
1
IMC-001
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Disulfides
1
Diathermy
1
Cisplatin
1
Cell- and Tissue-Based Therapy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.